A Phase 4 interventional study of Tirbanibulin ointment 1% in Warts Hand, sponsored by The Skin Center Dermatology Group. Completed at 1 site in United States. Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by The Skin Center Dermatology Group · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Warts with a site in United States — 7 open to participants now, 10 under way, 4 of them phase 3. Warts · United States.
Among the 59 studies in Warts with a site in United States, this one is the 55th largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2025, is one of 5 in phase 4, and was the 53rd registered.
172 studies on the registry are indexed under Warts; 36 are open to participants now.
Browse Warts studies →7 of the 59 studies in Warts with a site in United States are open now. Recruiting first, the newest first:
Verrica Pharmaceuticals Inc. · Sites in United States, Japan
Ages 2+
Verrica Pharmaceuticals Inc. · Sites in United States, Japan
Ages 2+
Western Institute for Veterans Research · Sites in United States
Ages 18+
The Skin Center Dermatology Group · Sites in United States
Ages 4+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 19 Warts studies recruiting now, 10 (53%) set no upper age limit and 9 (47%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.
This study: 8 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 29 · Phase 3 13 · Phase 4 5
First in 2004; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 70 across 156 interventional studies indexed under Warts.
Median enrollment 80 across the 58 interventional studies, 950 across the 1 observational. Of the 45 that completed or were terminated, 27 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 59 have an industry lead sponsor. The 10 most frequent:
The Skin Center Dermatology Group is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
The Skin Center Dermatology Group has 2 studies filed under Warts — fewer than ten, so there is no comparison to draw.
5 of the studies in Warts with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07246590Phase 3Verrica Pharmaceuticals Inc.Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) | 2026-11 |
| NCT07637734Phase 3Verrica Pharmaceuticals Inc.Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3) | 2027-05 |
| NCT07457918Phase 3Verrica Pharmaceuticals Inc.Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris) | 2027-11 |
| NCT07881952Verrica Pharmaceuticals Inc.Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5) | 2027-04 |
| NCT07806617Rush University Medical CenterIntralesional Gardasil-9 for the Treatment of Recalcitrant Warts | 2027-06 |
Add all 5 to your calendar (.ics) → With an account.
Among the 59 studies in Warts with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Warts are common, benign skin lesions caused by the human papillomavirus (HPV). Treatment is challenging, particularly in the pediatric population, where standard modalities such as cryotherapy and intralesional immunotherapy are poorly tolerated. Existing topical treatments, such as imiquimod and 5-fluorouracil, have low efficacy and require prolonged use. Case reports suggest tirbanibulin ointment may provide an effective and well-tolerated alternative for pediatric warts. This study will evaluate the efficacy and safety of tirbanibulin ointment in treating pediatric hand warts.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. intralesional immunotherapy 2. intralesional bleomycin, 5-fluorouracil, methotrexate 3. intralesional cidofovir 5. Any over the counter, prescription topical, or in-office procedural wart treatment within 6 weeks of baseline (Day 1) 6. Known immuno-suppressed state due to disease or medication, medical treatment o 7. Known allergy to any component of the IP 8. Any conditions that, in the Principal Investigator's opinion, may interfere with the course of the study
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Topical medication self-applied
Drug: Tirbanibulin ointment 1%
Topical application
Resolution
Ful resolution of treated lesions
Time frame: 2 months aftre completion of 4 or less treatment cycles
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from May 2025 to primary completion in Nov 2026, 18 months.
Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Nov 2026, on Nov 17, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirbanibulin
The Skin Center Dermatology Group